Speaking of semaglutide…
Semaglutide seems to be everywhere. News stories in The Wall Street Journal. Vanity Fair. The New York Times.
Semaglutide seems to be everywhere. News stories in The Wall Street Journal. Vanity Fair. The New York Times.
With release of the revised USP <797>, the compounding gods have spoken. But like Job in the Bible, we’ve got questions.
We welcome and congratulate these 2023 leaders of APC’s standing committees...
Are you up-to-speed on recent regulatory and practice protocol changes? Take a moment to assess yourself—and to see how you measure up with your peers…
APHA, NCPA, and APC sent a joint letter to FDA this week, urging the agency to take action on suspension shortages.
The report that accompanies the FDA appropriation bill recently signed by President Biden includes several compounding directives for the agency.
APC member TW Taylor with Williamsburg Drug in Williamsburg, VA, has been using Outcome MD for nearly nine months, and he reports that, so far, the platform has been an excellent resource for his compounding pharmacy.
This week we debut “What We’re Working on Right Now,” the first in what will be an ongoing series of short videos (under 4 minutes!) designed to keep our members in the know on APC’s advocacy activities.
APC’S Owner Summit 2023 is the year's premier in-person learning, planning, and idea-sharing event for compounding pharmacy owners and managers.
APC recently submitted a comment letter on DTE to the FDA docket outlining our concerns with the recent reclassification of DTE.